JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities has reiterated its Market Outperform rating for Crinetics Pharmaceuticals, maintaining a price target of $80.
September 27, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities has reiterated its Market Outperform rating for Crinetics Pharmaceuticals, maintaining a price target of $80, indicating confidence in the company's future performance.
The reiteration of a Market Outperform rating and maintenance of a high price target by JMP Securities suggests positive sentiment and confidence in Crinetics Pharmaceuticals' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100